MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2026 International Congress

    Portosystemic Shunt Related Parkinsonism in Acquired Hepatocerebral Degeneration With Persistent Pallidal T1 Hyperintensity

    A. Pronina, N. Fedotova, M. Usupova, E. Brill (Moscow, Russian Federation)

    Objective: To highlight acquired hepatocerebral degeneration as an underrecognized cause of secondary parkinsonism and to emphasize the diagnostic value of serial MRI in movement disorder…
  • 2026 International Congress

    Prediction of Cognitive Decline After STN-DBS in Parkinson’s Disease Using Preoperative Electroencephalography and a Deep Learning Model

    K. Iwami, K. Eguchi, S. Shirai, H. Yaguchi, I. Yabe (Sapporo, Japan)

    Objective: To determine whether preoperative electroencephalography (EEG) combined with deep learning can predict cognitive decline 1 year after subthalamic deep brain stimulation (STN-DBS) in patients…
  • 2026 International Congress

    Military-related associations with Parkinson’s disease (PD) in the Millenium Cohort Study

    S. Goldman, E. Richard, R. Rull, E. Boyko, K. Friedl, E. Hu, L. Liu, S. Boparai, N. Riedel, K. Comyns, E. Brown, C. Tanner (San Francisco, USA)

    Objective: To examine associations between military-related exposures and PD. Background: The Millennium Cohort Study is a large prospective cohort of 260,228 US service members and…
  • 2026 International Congress

    Immune-mediated Chorea in Antiphospholipid Syndrome: Normalization of FDG-PET and Neurofilament as Markers of Treatment Response.

    L. Peraferrer-Montesinos, J. Martínez-Rodríguez, A. Fernández-Lebrero, M. Viles-Garcia, E. Carrillo Villamizar, P. Plaza-López, V. Puente-Periz, I. Navalpotro-Gómez (Barcelona, Spain)

    Objective: To present a case where FDG-PET and neurofilament findings help portray the reversibility of neuronal damage in antiphospholipid syndrome (aPL).   Background: Chorea is the most common movement disorder in aPL and often an initial manifestation, although…
  • 2026 International Congress

    Subthalamic Nucleus Deep Brain Stimulation Modulates Cortical Activation During Kinesthetic Illusion in Parkinson’s Disease: An fMRI Study

    A. Vijayakumari, T. Gonzalez, C. Piccinin, P. Bhattacharyya, M. Lowe, B. Walter (Cleveland, USA)

    Objective: To investigate how subthalamic nucleus deep brain stimulation (STN-DBS) modulates cortical activation during kinesthetic illusion (KI) in Parkinson’s disease (PD). Background: There is increasing…
  • 2026 International Congress

    Medication Burden and Associated Challenges for People with Parkinson’s: A Survey of 359 UK Patients

    S. Jones, D. van Wamelen, S. Chapman, J. Patel (London, United Kingdom)

    Objective: To quantify medication burden among people with Parkinson’s disease (PD) and explore factors which contribute to medication experience in PD. Background: Individualised, complex medication…
  • 2026 International Congress

    Iron-independent initiation of neurodegeneration in BPAN

    S. Noda, N. Hattori (Bunkyo, Japan)

    Objective: Beta-propeller protein–associated neurodegeneration (BPAN) is caused by mutations in WDR45 and classified within the neurodegeneration with brain iron accumulation (NBIA) spectrum. Although brain iron…
  • 2026 International Congress

    Exploratory Results From a Phase 1 Study of NIO752 in Progressive Supranuclear Palsy Supporting Further Clinical Studies

    M. Brys, M-A. Valentin, S. Menon, N. Pezous, M. Meadowcroft, H. Gunduz-Bruce, C. Serban, L. Kovacic, M-E. Riviere, D. Singh Juneja, A. Graf, L. Vandevrede, G. Höglinger (East Hanover, USA)

    Objective: To report exploratory analyses of biomarker and clinical outcomes from a first-in-human study of NIO752 in progressive supranuclear palsy (PSP) and provide rationale for…
  • 2026 International Congress

    Perception of Early-Intervention Therapies and Clinically Meaningful Delays in Huntington’s Disease Onset and Progression: The Pre-HDBOI Study

    A. Toumadj, I. Rodriguez-Santana, C. Mighiu, A. Arnesen, B. Balas (Lexington, USA)

    Objective: To characterize willingness among people with premanifest Huntington’s disease (PwPHD) to consider early-intervention therapies if available, the minimally acceptable delay in HD onset/progression, and…
  • 2026 International Congress

    Real-world database analysis of new-onset hypotension and medications for orthostatic hypotension prescribing patterns in patients with Parkinson’s Disease receiving MAO-B Inhibitors and levodopa in Japan

    M. Nagai, R. Ando, K. Sasaki, Y. Tomita, K. Daidoji, Y. Kogo, T. Ishida (Ehime, Japan)

    Objective: To evaluate the incidence of claims-defined new-onset hypotension and the prescribing patterns of medications for orthostatic hypotension in patients with Parkinson’s disease (PD) treated…
  • « Previous Page
  • 1
  • …
  • 13
  • 14
  • 15
  • 16
  • 17
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley